Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit
Posted inCardiology General Surgery news

Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit

In high–cardiac-risk veterans after major vascular or general surgery, a liberal postoperative transfusion threshold (Hb <10 g/dL) did not reduce 90‑day death or major ischemic events compared with a restrictive threshold (Hb <7 g/dL); some non‑MI cardiac complications were less frequent with liberal transfusion.
Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial
Posted inCardiology news

Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

The DECAF randomized trial found that encouraging caffeinated coffee consumption (≈1 cup/day) after successful cardioversion reduced clinically detected AF/flutter recurrence over 6 months versus caffeine abstinence (47% vs 64%; HR 0.61). Results challenge routine caffeine restriction in AF patients but require confirmation and contextualization.
Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results
Posted inCardiology Gastroenterology news

Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results

Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher doses were linked to liver enzyme elevations, thrombocytopenia, and increased hepatic fat.
Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin
Posted inCardiology Neurology news

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while numerically more major bleeding occurred with rivaroxaban.
First-in-Human CRISPR-Cas9 Editing of ANGPTL3 Shows Dose‑Dependent Protein Knockdown with Acceptable Short‑Term Safety in Phase 1 Trial
Posted inCardiology news

First-in-Human CRISPR-Cas9 Editing of ANGPTL3 Shows Dose‑Dependent Protein Knockdown with Acceptable Short‑Term Safety in Phase 1 Trial

A phase 1, ascending‑dose study of CTX310 (LNP-delivered CRISPR-Cas9 targeting ANGPTL3) in 15 patients produced dose-dependent ANGPTL3 reductions at ≥0.6 mg/kg with few acute safety signals; longer follow‑up and larger trials are required to define efficacy, durability, and long-term risks.
No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials
Posted inCardiology news

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials

An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indications for beta blockade.
SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer
Posted innews Oncology Radiology

SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer

The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall survival benefit except possibly for pT3N0 disease.
Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs
Posted inDermatology news

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs

Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and fewer adverse events than deucravacitinib through 24 weeks.
High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening
Posted inGastroenterology news Psychiatry

High Burden of ARFID Symptoms in Adults with Disorders of Gut–Brain Interaction: A Population-Based Study Signals Need for Routine Screening

A 2023 population survey of 4,002 adults in the UK and US found that positive screens for avoidant/restrictive food intake disorder (ARFID) were common among people with disorders of gut–brain interaction (DGBI) and associated with greater health burden, underweight, poorer quality of life, and higher healthcare use.